Connect with us


Why SKDI May be Best of Breed in the CBD Space



For those looking to pick the bottom in CBD, we make the case here that a relative newcomer in the space, Sun Kissed Industries Inc. (OTCMKTS:SKDI), may actually provide the most explosive opportunity in the weeks and months ahead.

The key to this argument is our sense that SKDI is not well known by traders in the space because it entered commercial-stage operations in CBD by way of its acquisition of Hakuna Products late last year. In many ways, Sun Kissed is now the trading vehicle for Hakuna, and Hakuna is an exceptional story as a growing brand with strong potential in the space.

As noted by the company in its most recent release, Hakuna is an award-winning CBD-products company, currently nominated for “Best Hemp-Derived CBD Product” by the California Cannabis Awards after winning the DOPE Magazine Best New Product award for Southern California in the non-cannabis/non-tech category in 2017. Hakuna was also just awarded “Runner Up” at the Los Angeles Coffee & Donut Festival People’s Choice Coffee Awards for 2019.

Hakuna also boasts significant revenues with a substantial distribution footprint, including over 110 established retail distribution partners across over 20 states in the domestic US market.

In other words, we particularly like SKDI because we see it as a direct way to gain investment access to its wholly-owned subsidiary, Hakuna, which represents a ton of potential as a leading branded name in the CBD marketplace.

Upping the Stakes

To make matters even more interesting, SKDI just put out a press release this morning noting that Hakuna has initiated a series of measures to optimize operational efficiency, increase output, and drive a substantial increase in revenue growth over coming quarters.

This apparently includes a clean room, which is set to be fully operational over the next few weeks. According to the company, this process will up output by more than 50% and drive more than 30% in topline growth over the next 6 months.

The company’s CEO, Carl Grant, put it succinctly: “Hakuna has a very strong stable of award-winning products and a large nationwide distribution footprint in a booming market niche. But one of the reasons we acquired the company is our sense of low-hanging fruit on the vine. This is truly a top emerging brand in the high-end CBD-based products space. More output is going to mean a ramp in sales growth and a wider awareness of the Hakuna brand. At this point, this story is about scaling up and widening margins on variable cost inputs.”

According to the release, the gains in output will be driven by the new clean room, new equipment (including an industrial mixer, an industrial hopper, and a capsule packaging machine for coffee goods), and “a number of additional steps to streamline the operational sequence from order to shipment of product.” Besides gains on the topline, the company is also anticipating a sharp reduction in turnaround lag for new orders, with shipment going out in 48 hours rather than the current period of 5 days.

Hakuna management believes these steps will reduce the time lag between placement of a new order and shipment of that order by over 50% to just 48 hours, and increase overall output by over 50%. The net effect of these adjustments are expected to drive a jump in revenues of more than 30% over the next two quarters.



The CBD space has been wrecked by too many pretenders entering the space in a mad rush following the wild growth projections that started to hit Wall Street back in 2017-18. The huge influx of cheap supply and an overwhelming number of new brands and white labeled pretenders created a massive oversupply of both CBD and shares of CBD companies in the public markets.

Whenever that happens, you’re looking at a bear market that has one job: to wipe out the pretenders and clear the playing field for the survivors to flourish. The survivors in this type of scenario generally end up being those brands that manage to differentiate themselves.

Sun Kissed Industries Inc. (OTCMKTS:SKDI) is an easy way to pick up exposure to one of the brands that is already carving out a very promising foothold on differentiation through its award-winning products and wide footprint of distribution.

And the best part is: you have a chance right now to get on board before the crowd has found it.


TerrAscend Canada Inc, A Subsidiary Of Terrascend Corp (OTCMKTS:TRSSF), Enters A $80.5 Million CAD Loan Financing Accord With Canopy Growth Corp (NYSE:CGC)



TerrAscend Canada Inc, a subsidiary of Canopy Rivers Inc (OTCMKTS:CNPOF), has entered into an $80.5 Million CAD loan financing agreement with Canopy Growth Corp (NYSE:CGC). As per the terms of the deal, Canopy Growth has received 17.8 million common shares purchase warrants from TerrAscend.

Well-positioned to capitalize on opportunities

CEO and President of Canopy Rivers, Narbe Alexandrian, said it shows the confidence in TerrAscend’s capability to implement the strategic mandate for domestic and international markets. He said the team at TerrAscend is well-positioned to leverage the flourishing opportunities in the regulated jurisdictions using its network and resources. Narbe is pleased with the support extended by Canopy Growth for its portfolio company – TerrAscend.

Proceeds for general corporate purposes

TerrAscend Canada will use the proceeds to fund the Canadian operations and for general corporate purposes. It will also use the funds to repay indebtedness and to support global expansion and its Arise Bioscience U.S. hemp division.

Receives a permit to cultivate medical marijuana

TerrAscend has announced the receipt of a permit from the New Jersey Department of Health to cultivate medical marijuana. Its subsidiary TerrAscend NJ will commence the cultivation immediately at its facility situated in Boonton Township, northern New Jersey. It is the second entity in New Jersey among the six applicants selected in December 2018 by the Department of Health. TerrAscend NJ can commence manufacturing after the receipt of dispensing and additional processing approvals. It can manage up to three dispensaries in the northern area of New Jersey.

66,000 patients’ gains access to the medical marijuana program

More than 66,000 patients have gained access to the medical marijuana program as of January 2020 in New Jersey. The registered medical patients’ count has almost tripled since early 2018.

TerrAscend has purchased a sixteen-acre site in Boonton Township. It commenced the construction on an area of 227,000 Sq. Ft. under the first phase to cover cultivation, support space, and processing on 80,000 Sq. Ft. The first phase will become operational in H1 2020.

TerrAscend will supply the wholesale customers and its dispensaries by sourcing the cannabis products from its scaled cultivation capacity. It also expects to meet the demand for fifteen new retail dispensaries using cannabis from the scaled cultivation facility.

Continue Reading


Medipharm Labs Corp (OTCMKTS:MEDIF) Expects To Begin Supply Of Pharmaceutical-quality cannabis oil products in Australia



Medipharm Labs Corp (OTCMKTS:MEDIF) will supply pharmaceutical quality cannabis oil products in Australia. It is on the backdrop of a two-year agreement signed between Compass Clinics Australia Pty Ltd and MediPharm Labs Australia Pty Ltd.

Provides education and consultation services

Compass Clinics provides education and consultation services to Australian patients who look to access medical cannabis products. The company inaugurated its first two clinics last year in Australia. It will now commence the sale of its own branded products. Compass Clinics expects to inaugurate additional clinics in 2020. It offers consultation services for the patients, who want to get medical cannabis products via SAS (Special Access Scheme) or Authorized Prescriber pathways, in Australia. The company also uses the services of third-parties to sell cannabis oil and cannabis products.

Complies with minimum requirements to import cannabis

Chief Executive Officer of Medipharm Labs, Pat McCutcheon, said the company is excited to work with leading players like Compass Clinics to provide high-quality cannabis products to medical patients in Australia. The partnership with Cannabis Clinics helps the company to comply with the minimum requirements set by the Australian Government to import cannabis products.

Recently received import licenses, and Australian GMP certification helps the company to increase demand for its Pharma quality products. It also helps to expand its presence in the emerging worldwide markets and Australia.

Distribution of cannabis oil products in Australia

Medipharm Labs Australia will commence the supply of white-labeled cannabis oil under the trademark of Compass Clinics. The company will start receiving the formulated cannabis oil products from the Canadian TGA GMP certified facility of Medipharm Labs. It will distribute imported cannabis oil products to Compass Clinics in Australia.

President of Compass Clinics, David Martyn, said the company is pleased to offer GMP certified best-in-class, and pharmaceutical grade gel caps and cannabis oils to the growing patient base in Australia. He said Compass Clinics will benefit from its association with a leading producer of cannabis products – Medipharm Labs in serving its prevailing patient base. It also helps to expand its footprint in the surging medical cannabis space worldwide.

New scheduling status for CBD

The Australian authorities expect to consider a new scheduling status for cannabidiol. It expects to ensure the availability of CBD in low dosages early this year. The TGA is currently reviewing the safety of lower dosages of CBD.

Continue Reading


Kannalife Inc (OTCMKTS:KLFE) Announces Receipt Of Australian Patent To Treat Hepatic Encephalopathy



Kannalife Inc (OTCMKTS:KLFE), a portfolio company of Medical Marijuana Inc (OTCMKTS:MJNA), has received an Australian patent No. AU2015204609B2, which is specific to the Novel Functionalized 1,3-Benzene Diols as well as their method to cure Hepatic Encephalopathy. Kannalife owns seven patents across the world.

Committed to widen cannabis knowledge

Chief Executive Officer of Medical Marijuana, Dr. Stuart Titus, said Kannalife and Medical Marijuana are committed to accepting cannabinoid and cannabis-related studies and widening knowledge worldwide. Kannalife is embarked on this target with new patients in six nations.

KLS-13019, a leading candidate in the intellectual property of Kannalife, can act as a neuroprotective agent to cure a wide range of diseases that comprise neurodegenerative disorders, oxidative stress, and nervous system disorders. Chief Executive Officer of Kannalife, Dean Petkanas, said the company is pleased that several jurisdictions recognized its Intellectual Estate as proprietary and novel.

The patent is vital to commercialize KLS-13019

The receipt of an Australian Patent is an important step in gearing towards commercializing its leading drug candidate – KLS-13019 soon. It expects to market the drug in the pharmaceutical market of Australia. The demand for Australian pharmaceuticals expects to reach $32.1 billion this year.

After applying for PCT patent in 2015, Kannalife received the following patents:

The US Patent No 10,044,722 “a method to cure hepatic encephalopathy or diseases related to the free radical medical stress as well as oxidative stress using novel functionalized 1,3-benzene diols.”

The US Patent No 9,611,213 “an innovative functionalized 1,3-Benzene Diols and their methods to cure hepatic encephalopathy”.

The company also received Russian and Japanese patents.

Kannalife commences trading on the OTC markets

Kannalife is pleased to announce that it commences trading under the ticker symbol – KLFE on the OTC markets. After becoming an investor in Kannalife in 2013, Medical Marijuana now holds a stake of 26.17%.

Stuart said the company is excited that the general public and investors can contribute to the funding of Kannalife’s R&D programme in cannabinoid-therapeutics. The market for cannabinoid-based pharmaceuticals in the US expects to reach $50 billion in the next decade. Marijuana, as an early investor in Kannalife, believes that its portfolio of IP assets and ground-breaking research helps the company to stay ahead in the race.

Continue Reading


Business9 hours ago

TerrAscend Canada Inc, A Subsidiary Of Terrascend Corp (OTCMKTS:TRSSF), Enters A $80.5 Million CAD Loan Financing Accord With Canopy Growth Corp (NYSE:CGC)

Post Views: 173 TerrAscend Canada Inc, a subsidiary of Canopy Rivers Inc (OTCMKTS:CNPOF), has entered into an $80.5 Million CAD...

Business1 day ago

Medipharm Labs Corp (OTCMKTS:MEDIF) Expects To Begin Supply Of Pharmaceutical-quality cannabis oil products in Australia

Post Views: 394 Medipharm Labs Corp (OTCMKTS:MEDIF) will supply pharmaceutical quality cannabis oil products in Australia. It is on the...

Business2 days ago

Kannalife Inc (OTCMKTS:KLFE) Announces Receipt Of Australian Patent To Treat Hepatic Encephalopathy

Post Views: 308 Kannalife Inc (OTCMKTS:KLFE), a portfolio company of Medical Marijuana Inc (OTCMKTS:MJNA), has received an Australian patent No....

Business3 days ago

SinglePoint, Inc. (OTCMKTS:SING) Unveils Hemp Seed Oil Infused Hand Sanitizer – Klen Hands To Combat Coronavirus

Post Views: 397 SinglePoint, Inc. (OTCMKTS:SING) has unveiled hemp seed oil infused hand sanitizer – Klen Hands to help people...

Business6 days ago

CV Sciences Inc (OTCMKTS:CVSI) Reports Revenues Of $53.7 Million In 2019: Increases Retail Distribution Footprint To Over 5,500 Stores

Post Views: 662 CV Sciences Inc (OTCMKTS:CVSI) has reported revenues of $53.7 million (up 11%) in 2019. It also increased...

Business1 week ago

Aleafia Health Inc (OTCMKTS:ALEAF) Reports Robust Revenues Of $6.028 Million In Q4 2019

Post Views: 424 Aleafia Health Inc (OTCMKTS:ALEAF) has reported revenues of $6.028 million in Q4 2019. It is an increase...

Whats Hot